Trending Articles

article thumbnail

Efficacy of Tapinarof Cream 1% Demonstrated in Atopic Dermatitis in Skin of Color

Drug Topics

A lack of diversity in clinical trials has hampered health care providers from understanding the nuances of diseases across specific patient populations.

98
article thumbnail

CAR-Ts set to move earlier in multiple myeloma therapy

pharmaphorum

FDA advisors have said that two BCMA-targeted CAR-T therapies can be used earlier in the treatment pathway for multiple myeloma, setting up FDA approvals for use in a broader patient population.

FDA 112
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

How Daylight Saving Time Increases Overall Health Risks

Drug Topics

Recent studies on daylight saving time’s association with increased health risks have heightened the debate on whether to observe the biannual event or switch to one universal time.

201
201
article thumbnail

Inside a push to create an NIH office for post-infection chronic illness

STAT

When the White House released President Biden’s 2025 budget requests this week, funding for biomedical research was stagnant. The more conservative wishlist from the president acknowledges a reduced appetite in Congress for non-defense government spending.  But some disease groups, along with their research allies, are undeterred. A growing number are calling for increased research funding and the creation of a new body at the National Institutes of Health to study chronic conditions

145
145
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

With Pfizer struggling in 2023, CEO Bourla hit with 35% pay cut to $21.6M

Fierce Pharma

Pfizer knew 2023 was going to be a challenging year of transition. But even the drugmaker was surprised by the plummeting demand for its COVID-19 products, missing badly on its 2023 guidance. | After a difficult year for Pfizer, in which its share price fell by 44%, CEO Albert Bourla’s compensation fell by 35% from $33 million in 2022 to $21.6 million in 2023.

145
145
article thumbnail

Pharmacy Focus: Limited Series: Celebrity Endorsements in Ozempic

Pharmacy Times

This podcast episode discussed the impact of celebrity endorsements on trends in weight loss drugs like Ozempic, body image issues, and the role of pharmacists in educating patients on appropriate use of GLP-1 medications for weight management and chronic diseases.

139
139

More Trending

article thumbnail

CDC Says US Will Transition to Trivalent Vaccines Next Flu Season

Drug Topics

Since changes in vaccine composition can sometimes lead to confusion or misinformation, effective communication is crucial to promote vaccine uptake.

Vaccines 200
article thumbnail

STAT+: Medicare couldn’t cover Wegovy for weight loss. But now that it’s also a heart drug, the door is open

STAT

WASHINGTON — Novo Nordisk’s newly won permission to market the heart benefits of its obesity drug Wegovy could provide a backdoor way to expand access to the drug for people on Medicare, experts told STAT. Currently, Medicare is prohibited by law from covering medications for obesity treatment alone. While companies that manufacture wildly popular anti-obesity medications and their allies haven’t been successful in lobbying Congress to change the law , the Food and Drug

Labelling 145
article thumbnail

Despite early death concerns, FDA advisers back J&J and Legend's Carvykti for earlier myeloma

Fierce Pharma

Even though the BCMA CAR-T therapy Carvykti showed a potential problem of early patient deaths in a trial, experts on the FDA’s Oncologic Drugs Advisory Committee (ODAC) still believe that the drug | Even though the BCMA CAR-T therapy Carvykti showed a potential problem of early patient deaths in a trial, experts on the FDA’s Oncologic Drugs Advisory Committee still believe that the drug’s long-term benefits outweigh its risks.

FDA 123
article thumbnail

Study: Only 40% of Adults With Childhood Asthma Experience Remission

Pharmacy Times

The study showed no clinical differences for remission or asthma at age 28 years based on lung function, body mass index, daily smoking, exposure to parental tobacco smoke, or house dampness.

132
132
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

AHA: 94% of hospitals financially impacted by Change Healthcare's cyberattack

Fierce Healthcare

Nearly every hospital is feeling the consequences of Change Healthcare’s cyberattack on their finances, patient care delivery, or both, according to reports from almost 1,000 hospitals compiled by | Almost 60% of surveyed hospitals reported at least $1 million of impacted revenues per day, and 74% said that the incident has had "direct" implications on patient care within their facilities.

Hospitals 124
article thumbnail

Psilocybin Analog for Treatment of Depression Receives FDA Breakthrough Therapy Designation

Drug Topics

Cybin’s proprietary deuterated psilocybin analog, CYB003, provided robust and sustained improvements in depression symptoms in a phase 2 study.

FDA 198
article thumbnail

Study: Gilead antiviral drug shows promise as a treatment for Ebola Sudan

STAT

A new study suggests the antiviral drug obeldesivir may be effective in curing Ebola Sudan infections, for which there are currently no approved vaccines or treatments. Scientists at the University of Texas Medical Branch in Galveston tested the drug, made by Gilead, in primates, starting treatment 24 hours after the animals were given what should have been a lethal dose of Sudan ebolavirus by intramuscular injection.

Vaccines 145
article thumbnail

Novartis lays out $256M for antibody plant expansion in Singapore, plots 100 hires

Fierce Pharma

Over the years, Singapore has attracted a suite of biopharma majors, and Novartis is no exception. | Novartis broke ground on a $256 million expansion of its biopharmaceutical production facility in Singapore. The project will introduce digitalization and automation at the site in a bid to boost manufacturing productivity and to help upskill the company’s workforce.

120
120
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

FDA Approves Maralixibat for Treatment of Pediatric Patients With PFIC

Pharmacy Times

The drug is indicated for patients 5 years of age and older with progressive familial intrahepatic cholestasis and cholestatic pruritus in pediatric patients with Alagille syndrome.

FDA 132
article thumbnail

Eli Lilly partners with Amazon Pharmacy for home delivery of its weight loss, diabetes and migraine drugs

Fierce Healthcare

Eli Lilly is partnering with Amazon's pharmacy unit to offer home delivery for diabetes, migraine and obesity medications, including GLP-1 weight loss drug Zepbound. | Eli Lilly is partnering with Amazon's pharmacy unit to offer home delivery for diabetes, migraine and obesity medications, including GLP-1 weight loss drug Zepbound.

130
130
article thumbnail

FDA Approves Resmetirom as First-Ever Treatment For MASH

Drug Topics

The approval, awarded to Madrigal Pharmaceuticals, was based on phase 3 data demonstrating that resmetirom achieved broad treatment effects in patients with MASH with liver fibrosis.

FDA 131
article thumbnail

What the brains of song birds can teach us about human stuttering

STAT

A symphony of synapses fires every time a songbird sings. For Erich Jarvis, a neurobiologist at Rockefeller University, the neural pathways he finds particularly interesting inside a birds’ brain are those that enable the bird to make new sounds from listening to their environment. This is an ability known as vocal learning, and is perhaps most notably exhibited when a parrot mimics a person’s speech (or profanity).

141
141
article thumbnail

Study: Researchers Identify 25 Air Pollutants Associated With Asthma Symptoms

Pharmacy Times

Investigators found that 1,1,1 trichloroethane; 2-nitropropane; and 2,4,6 trichlorophenol were significantly associated with asthma symptoms for 3 exposure periods.

144
144
article thumbnail

HIMSS24: 'Fasten your seatbelts'—Hackensack Meridian CEO predicts acceleration of gen AI to help healthcare workforce

Fierce Healthcare

ORLANDO — It's almost impossible to have a conversation at HIMSS24 without the topic of artificial intelligence or generative AI coming up. | How will the conversations about AI in healthcare change by next year's HIMSS conference? Hackensack Meridian CEO Robert Garrett predicts that pilot projects underway now will roll out into practice.

130
130
article thumbnail

Opinion: No parent who has seen the children I’ve treated for measles would refuse a vaccine

STAT

Over the past year, I have watched many children die of measles. In the final stages, little lungs, filled with fluid and racked with inflammation, struggle for oxygen. The victims breathe faster and faster, gasping for air until, exhausted, they stop.

Vaccines 145
article thumbnail

Biotech trade group pledges support for BIOSECURE Act, plans to boot member WuXi AppTec

Fierce Pharma

As CDMO giants Wuxi AppTec and WuXi Biologics come under mounting scrutiny for their alleged ties to Chinese government officials, they are losing a key ally in Washington, D.C. | As CDMO giants Wuxi AppTec and WuXi Biologics come under mounting scrutiny for their alleged ties to Chinese government officials, they are losing a key ally in Washington, D.C.

116
116
article thumbnail

FDA Breakthrough Therapy Designation Granted to Novel Psychedelic Molecule CYB003 for Major Depressive Disorder

Pharmacy Times

At 4 months, 75% of participants achieved remission and no longer showed signs of depression symptoms in a phase 2 clinical trial.

FDA 149
article thumbnail

Becerra to stakeholders: It's time to take accountability for cybersecurity

Fierce Healthcare

Cybersecurity concerns sucked up much of the air in the room during President Joe Biden's proposed 2025 fiscal year budget briefing amid the ongoing Change Healthcare cyberattack drama. | HHS is telling providers its time to invest in cybersecurity or risk the consequences. Here's what Biden's budget proposes.

128
128
article thumbnail

A Pharmacy Consult with a Patient living with Bipolar I Disorder, Previously Using Oral Antipsychotics and Considering LAIs

Drug Topics

This video was sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. in collaboration with Lundbeck LLC.

98
article thumbnail

Rigid rules at methadone clinics are jeopardizing patients’ path to recovery from opioid addiction

STAT

DETROIT — Every morning, Rebecca Smith, nursing a surgically repaired knee, carefully walks down the hallway of her brutalist brick apartment building, takes the elevator one floor to the lobby, and negotiates the sharply angled driveway outside. There, she waits for an Uber to take her to the last place she wants to go: her methadone clinic.

145
145
article thumbnail

FDA flags early deaths in CAR-T myeloma trials for J&J and Legend’s Carvykti, Bristol Myers’ Abecma

Fierce Pharma

The FDA has raised concerns about early clinical trial deaths as part of two applications that aim to move the CAR-T therapies Carvykti and Abecma into earlier lines of treatment for multiple myelo | Ahead of an important advisory committee meeting, the FDA has raised concerns about early trial deaths for multiple myeloma cell therapies. At the meeting, experts will discuss applications that aim to move the CAR-T therapies Carvykti and Abecma into earlier lines of treatment.

FDA 110
article thumbnail

A Pharmacist’s Guide to Continuous Glucose Monitoring

Pharmacy Times

This guide discusses the integration of continuous glucose monitoring (CGM) technology into clinical practice, emphasizing the role of pharmacists in selecting and optimizing CGM devices for patients.

131
131
article thumbnail

Behavioral and veterans' health among key priorities in Biden's budget

Fierce Healthcare

President Joe Biden's 2025 budget did not just touch upon cybersecurity, the drug price negotiation program and Medicare solvency, as the plan also suggested policy for mental health, health equity | Many significant policy items in Biden's proposed 2025 fiscal year budget don't grab the initial headlines, but he's looking to make strides in mental health, substance use disorder and maternal health.

124
124
article thumbnail

AstraZeneca buys rare disease firm Amolyt for $1.05bn

pharmaphorum

AstraZeneca adds a late-stage rare disease therapy to its pipeline, buying Amolyt Pharma and hypoparathyroidism drug eneboparatide for $800 million upfront.

115
115
article thumbnail

STAT+: Small studies offer hope CAR-T can fight an aggressive brain cancer

STAT

A series of new studies are raising hopes that CAR-T , a process in which treatments are made by genetically editing a patient’s own white blood cells, can eventually be used to treat an incurable and deadly type of brain cancer, called glioblastoma multiforme, or GBM. In the most dramatic result, from a three-person study conducted by researchers at Massachusetts General Hospital, a 72-year-old man saw his tumor shrink 18.5% in just two days and then decrease further over the next two mo

Hospitals 144
article thumbnail

8 Ways to Cope with a Disappointing Residency Match 

Board Vitals - Pharmacist

You’ve worked tirelessly through years of medical school, and the culmination of your efforts has finally arrived: the residency match. While you may be excited to have matched, it can be disappointing to realize you matched into a program lower on your preference list, especially as watch your classmates celebrate their own successes. It’s okay to feel disappointed, and it’s natural to have envisioned a different outcome after investing so much time and effort into your medica

article thumbnail

GZ17-6.02 Effective in Killing Multiple Myeloma Cells, Other Benefits When Combined With Bortezomib

Pharmacy Times

The combination of GZ17-6.02 and bortezomib reduced of HDAC, and as a result ATG13 phosphorylation was enhanced, BAK levels increased, and BCL-XL levels were reduced.

132
132
article thumbnail

Senate Finance Committee grills Becerra on HHS' delayed relief in Change Healthcare cyberattack

Fierce Healthcare

Leading senators want Department of Health and Human Services, insurers and hospitals alike to know they’re keeping a close eye on the fallout from Change Healthcare’s cyberattack. | Influential senators held HHS Secretary Xavier Becerra's feet to the fire on Thursday, urging him and his department to deliver prompt support and maintain pressure on the industry to invest in cybersecurity.

Insurance 114